Patents by Inventor Rachael Ancliff

Rachael Ancliff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS
    Publication number: 20100075953
    Abstract: The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
    Type: Application
    Filed: September 18, 2009
    Publication date: March 25, 2010
    Applicant: Glaxo Group Limited
    Inventors: Rachael Ancliff, Colin David Eldred, Ashley Paul Hancock, Thomas Daniel Heightman, Heather Hobbs, Simon Teanby Hodgson, David Matthew Wilson
  • Morpholin-acetamide derivatives for the treatment of inflammatory diseases
    Publication number: 20060079525
    Abstract: There are provided according to the invention, novel compounds of formula (I) wherein R1, R2, R3, R4, R5, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Application
    Filed: November 22, 2005
    Publication date: April 13, 2006
    Inventors: Rachael Ancliff, Caroline Cook, Colin Eldred, Paul Gore, Lee Harrison, Simon Hodgson, Duncan Judd, Suzanne Keeling, Xiao Lewell, Graeme Robertson, Stephen Swanson
  • Novel compounds
    Publication number: 20060063765
    Abstract: Compounds of formula (I): wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents —(CRnaRnb)n—; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5; R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R3 and R4 each independently represent hydrogen or C1-6alkyl; R7 represents hydrogen or C1-6alkyl; R8 represents hydrogen or C1-6alkyl; and salts and solvates thereof; are CCR3 antagonists and are thus indicated to be useful in therapy.
    Type: Application
    Filed: March 27, 2003
    Publication date: March 23, 2006
    Inventors: Rachael Ancliff, Caroline Cook, Colin Eldred, Paul Gore, Lee Harrison, Martin Hayes, Simon Hodgson, Duncan Judd, Suzanne Keeling, Xiao Lewell, Gail Mills, Graeme Robertson, Stephen Swanson, Andrew Walker, Mark Wilkinson
  • N-2s-4-3,4-difluorobenzyl morpholin-2yl methyl -2-(3-methylsulphonyl amino!phenyl acetamide as ccr3 antagonist for the treatment of inflammatory conditions
    Publication number: 20060058299
    Abstract: Compound of formula (I): and salts and solvates thereof, a process for its preparation, pharmaceutical formulations containing it and its use in therapy.
    Type: Application
    Filed: March 27, 2003
    Publication date: March 16, 2006
    Inventors: Rachael Ancliff, Caroline Cook, Colin Eldred, Paul Gore, Lee Harrison, Martin Hayes, Simon Hodgson, Duncan Judd, Suzanne Keeling, Xiao Lewell, Gail Mills, Graeme Robertson, Stephen Swanson, Andrew Walker, Mark Wilkinson